(NYSE: BIO) Bio Rad Laboratories's forecast annual revenue growth rate of 2.24% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.69%.
Bio Rad Laboratories's revenue in 2026 is $2,589,300,000.On average, 7 Wall Street analysts forecast BIO's revenue for 2026 to be $69,759,898,575, with the lowest BIO revenue forecast at $67,273,248,300, and the highest BIO revenue forecast at $72,834,788,700. On average, 7 Wall Street analysts forecast BIO's revenue for 2027 to be $71,791,999,875, with the lowest BIO revenue forecast at $69,091,444,200, and the highest BIO revenue forecast at $75,000,580,875.
In 2028, BIO is forecast to generate $74,038,006,575 in revenue, with the lowest revenue forecast at $71,711,785,350 and the highest revenue forecast at $77,059,420,350.